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Abstract
Background: Stereotactic-guided breast biopsy is an invincible tool to sample abnormalities visible only on 
mammography with subtle or occult ultrasound findings. Common mammographic abnormalities which require 
stereotactic core biopsy include calcifications, architectural distortion and satellite lesions. With advancement in 
techniques for adequate localisation of lesions, the use of stereotactic needle breast biopsy is exponentially increasing. 
A study was performed to look for frequency of benignancy or malignancy of microcalcifications and architectural 
distortions in patients initially falling in malignant category of Breast Imaging-Reporting and Data System of American 
College of Radiology (BI-RADS®) Assessment Categories.
Materials and Methods: Patient presenting in outpatient (OPD) clinic who underwent stereotactic biopsies for 
labelled malignant on mammograms from May 2015 to May 2018 was included in retrospective study. Age, technique 
used, baseline mammogram and histopathology were reviewed.
Results: A total of 91 patients underwent stereotactic biopsy. Age range varied between 28 and 81 years. Stereotactic-
guided biopsies were taken using a standard 14-gauge core needle with long throw of 22 mm excursion. None of 
the biopsy was inconclusive. In comparison with baseline mammograms and histopathology, 40% of the clusters of 
microcalcification which were initially labelled as malignant turned out to be malignant on histopathology as well, 
whereas 60% were reported as benign breast parenchyma.
Conclusion: Agreement between the diagnostic accuracy of microcalcifications on mammogram and histopathology 
of same lesions after stereotactic biopsy was comparable to international figures with probability of being benign 
surpassing malignant on routine screening.
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Introduction
With recent advancement in imaging techniques and 
increased levels of patient awareness and education, a 
large population of women, most of them 40 years or 
older, undergo screening mammography. This has led to 
increased detection of the early and often non-palpable 
breast cancer, reducing overall breast cancer mortality and 
morbidity over the past few decades.[1,2]
The field of breast interventions has profited immensely 
from recent evolution in imaging. Pointing out the lesion, 
however, is only the starting point. Once the lesion is 
perceived, the challenge is to then aptly diagnose it in 
as minimally invasive a way as possible. This, in turn, 
determines the course of patient’s entire management.
In the recent past, tomosynthesis, a latest 3-D mammographic 
technique, has proved itself in increasing the diagnostic 
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accuracy of breast cancer detection rates. It is predicted 
that tomosynthesis will lead digital mammography 
in the upcoming years. In patients with suspicious 
breast lesions identified on baseline mammography or 
tomosynthesis, stereotactic-guided biopsy is one of the 
many available options for obtaining the tissue essential 
for histopathological diagnosis. Usually, the lesions 
undergoing stereotactic biopsies are occult on ultrasound 
and typically present with microcalcification or an area of 
architectural distortion detected on mammography.
Clustered suspicious microcalcifications can be a very 
early sign of malignancy, particularly in ductal carcinoma 
in situ (DCIS). Microcalcifications are usually detected 
on screening mammographies, thus require stereotactic 
guidance for biopsy.[2,3]
In this paper, we aim to present our biopsy method and 
retrospectively evaluate the results and compare them 
with the final histopathological diagnosis in all patients 
undergoing stereotactic-guided biopsies performed over 
a 3-year period in our tertiary care oncological setup.
Materials and Methods
Between May 2015 and May 2018, 91 patients were 
referred to our clinic for stereotactic biopsy. These patients 
had non-palpable microcalcifications, sonographically 
occult architectural distortions or mass lesions for 
which they underwent a stereotactic biopsy. Biopsy was 
successfully performed in all 91 of these patients. Of 
these, 10 patients were excluded because biopsy was 
performed for mass/architectural distortions and not 
microcalcifications. The remaining 81 patients (median 
age 53 years, range 28–81 years) were included in the 
study. Biopsy was performed for 85 lesions, all of which 
were mammographically detected and could not be 
identified on US. Informed consent forms regarding the 
procedure of biopsy and academic use of data were signed 
by all patients. The institutional review board did not ask 
for any further approval as this is a retrospective analysis 
of the results [Figures 1 and 2].
Before biopsy, lesions were classified according to the 
new edition of mammographic BI-RADS classification 
published in 2015 [Table 1]. 21 lesions comprising 
amorphous calcifications were labelled as BI-RADS 
4A and 25 lesions comprising coarse heterogeneous 
calcifications were characterised as BI-RADS category 4B 
(87.38% in total). 35 lesions comprising fine pleomorphic, 
fine linear or branching calcifications were classified as 
BI-RADS category 4C/5.
We had no standard prebiopsy restrictions, patients with 
deranged coagulation profile and those on anticoagulants 
were screened. Some centres prefer to stop administering 
blood-thinning agents before biopsy. Patients are 
instructed to discontinue aspirin and NSAIDs 1 week 
before the procedure. An international normalised ratio 
level of <1.5 is confirmed on the day of the biopsy.
Lesions that pose difficulty to biopsy under stereotactic 
guidance include lesions that are lying very deep in the 
breast, are high in the upper outer quadrant and overall 
smaller breast size.
Biopsies were performed using a prone biopsy table 
(Multicare Platinum; Hologic) with 14-gauge (BARD) 
Figure 1: Images from stereotactic biopsy performed with 
targeting callipers placed on the lesion. Pre-fire image pair at 
−15° and +15° from midline
Figure 2:  Post-specimen radiograph demonstrates 
microcalcification indicating adequate sampling
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biopsy device having 22 mm excursion. Five cores were 
taken in each case. The best approach to the lesion was 
established by reviewing the mammogram beforehand. 
Craniocaudal and mediolateral views were taken 
before targeting the lesion. After acquiring the scout 
view, paired (+15 and −15) images were obtained for 
accurate needle placement using the x-y-z coordinates 
determined by the machine. Then, a local anaesthetic 
was applied and the needle was parked in the breast. 
Further, pre- and post-fire stereo images were acquired. 
The whole procedure took around 30 min which decreased 
further as our experience increased and we modified our 
technique over the time. Most of the patients tolerated the 
procedure really well. Post-biopsy tissue specimen was 
placed in a Petri dish, and radiography was performed. 
Specimen graphy was acquired in all lesions. The 
biopsy of a microcalcification cluster was rendered 
technically adequate if microcalcifications were identified 
histologically and/or on the radiograph of the specimen. 
There were no specific post-biopsy care instructions.
After a discussion at the multidisciplinary team meeting, 
patients with a histologic diagnosis of atypia, infiltrating or 
in situ carcinoma and surgical excision were recommended. 
Mammographic follow-up was recommended for the 
remaining patients with benign biopsy results. All patients 
had at least 1 year of follow-up.
Results
Stereotactic-guided biopsy results revealed 32 (39.8%) 
malignant lesions including DCIS (22.2%), infiltrative 
ductal carcinoma (14.8%) and infiltrative lobular 
carcinoma (0.02%). Findings at ensuing surgery confirmed 
malignancy in all 32 lesions. 3 (4%) of the lesions were 
atypical ductal hyperplasia and none were atypical 
lobular hyperplasia. No atypical hyperplasia lesions 
were upgraded to invasive carcinoma. The histologic 
results were benign in 46 (60.2%) of 81 lesions. None 
of the biopsies were inconclusive. Repeat biopsies were 
performed in four cases where the suspicion of malignancy 
was high. Out of the benign lesions, stromal hyperplasia 
dominated and accounted for 16 lesions (34.7%), fibrosis-
adenosis made up 13 (28.2%) of the lesions. 05 (10.8%) 
of these were sclerosis adenosis and fibrocystic changes 
each. Fat necrosis was found in 4 (8.69%) lesions, whereas 
lactational changes were diagnosed in 1 (2.17%) case. 
It was no surprise to find fibroadenomatoid lesions in 
2 (4.34%) of the clustered microcalcifications [Table 2].
Discussion
The main aim of performing a percutaneous biopsy is 
to be able to formulate an apt histologic diagnosis by 
obtaining an emblematic sample from what may be a 
radiologically suspicious lesion. We want to circumvent 
a false-negative biopsy result and also to minimise the 
chance of underestimation in case of DCIS and atypia.
Image-guided percutaneous breast biopsy is a cost-
effective and safe method of formulating an accurate 
Table 1: Bar chart displays the various categories that were 
assigned to all the lesions that ultimately were subjected to 
stereotactic biopsy
Table 2: Histologic diagnoses on stereotactic breast 
biopsy
Histologic diagnoses n (%)
Benign lesions (n=46)
Fibrosis‑adenosis 13 (16)
Fibroadenoma and fibroadenomatoid lesions 2 (2.5)
Fibrocystic changes 5 (6)
Sclerosing adenosis 5 (6)
Benign stromal hyperplasia 16 (20)
Fat necrosis 4 (5)






Atypical ductal hyperplasia 3 (4)
DCIS: Ductal carcinoma in situ, ILC: Invasive lobular carcinoma, 
IDC: Invasive ductal carcinoma
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tissue diagnosis of breast abnormalities. It has replaced 
surgical biopsy as the modus operandi for establishing 
diagnosis of most breast lesions, precluding surgery when 
benign pathology results are demonstrated or allowing for 
definitive upfront surgical treatment in most malignant 
cases.
Approximately 70–90% of the 1.6 million breast 
biopsies performed in 1 year, in the US are image-
guided percutaneous procedures. Stereotactic, US 
and MR guidance are all reassuring methods for 
performing image-guided biopsy. US-guided biopsy 
is the preferred method due to its speed, cost, patient 
comfort and real-time capabilities. However, for 
sonographically occult lesions, microcalcifications and 
architectural distortions which are not well-visualised 
sonographically, stereotactic biopsy is the favoured 
method. With all biopsy methods, careful attention to 
technique and radiologic-pathologic concordance are 
needed for a positive outcome.[1,2]
Stereotactic-guided biopsy is an outpatient procedure 
where general anaesthesia is not necessary and is less 
invasive, carrying almost no risks. Considering that 
significant number of women is undergoing screening 
mammography, an increased number of breast biopsies 
are being recommended. It is usually expected that most 
of these lesions are benign and this minimally invasive 
technique spares patients from undergoing expensive and 
potentially deforming surgeries.
In our study, we basically categorised various 
microcalcifications in both cancer and non-cancer 
patients, according to the latest mammographic BI-RADS 
classification published in 2015. These patients ultimately 
underwent stereotactic biopsies, and then, we correlated 
their histological diagnosis to see the extent to which these 
lesions were adequately classified radiologically.
Various factors that were considered during our trial 
included the number of specimens, radiograph after the 
procedure to assess if correct set of calcifications has 
been sampled. Obtaining large numbers of specimens 
were not that useful for an accurate diagnosis, it was an 
adequate number of correctly targeted specimens which 
is more beneficial.[4]
Radiography of the specimen for the detection of 
microcalcifications was introduced by Meyer et al.[5] 
and Lieberman et al.[6] and is an indicator of adequate 
sampling of the targeted microcalcifications. At times, 
microcalcifications were not seen on the post-procedure 
radiography, however, were diagnosed histopathologically.
The addition of digital add-on mammography and the 
vacuum-assisted needles to stereotactic breast biopsy 
equipment have immensely helped in decreasing 
procedure duration and the tissue sampling errors. It also 
offers the advantage of lower cost[7] and requires less 
space than a dedicated prone unit. Moreover, the setup 
can be utilised to do routine mammography when biopsy 
procedures are not being done.
In addition to this, with the introduction and increased 
clinical use of digital breast tomosynthesis, there is 
improved visualisation of masses and architectural 
distortions. There is substantial evidence that dialectical 
behaviour therapy (DBT) leads to a higher breast cancer 
detection rate by 31%[8] over that with conventional 
full-field digital mammography. DBT along with 
the vacuum-assisted needle is effective in retrieving 
microcalcifications, leading to adequate sampling and 
increased cancer detection overall.[2]
Our results indicate that stereotactic-guided breast 
biopsies are safe and cost-effective method of establishing 
a diagnosis and can be performed effectively without any 
substantial risks. Most of the microcalcifications identified 
on digital mammography fall in benign category even in 
cancer patients. However, the mammograms labelled as 
highly suspicious or those classified as category 4C/5 
almost always turned out to be malignant.
We also concluded that proper visualisation of the 
microcalcifications on the preprocedural radiographs of 
the breast and adequate positioning of the biopsy needle 
before obtaining tissue samples adds more substance to 
successfully retrieve microcalcifications, than is extraction 
of a larger number of tissue samples.
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